Use of LPC antagonist, choline, in the management of bronchial asthma

Indian J Chest Dis Allied Sci. Apr-Jun 1997;39(2):107-13.

Abstract

The present study was conducted to compare the effects of disodium cromoglycate (DSCG) and choline, a lipotropic factor, in management of bronchial asthma. Two groups taking DSCG and choline were compared between themselves and with a control group (on bronchodilators only) in a three month trial. A significant improvement in average symptoms scores was observed in all groups but was clinically significant only in the groups taking choline. Percent asymptomatic days increased in all the groups, but was not significant. The additional drug requirement decreased significantly only in the group taking choline. All groups showed an improvement in SGaw at FRC and percent fall in specific airways conductance (SGaw) at RV, but non-significant. A significant fall in bronchial hyperreactivity (BHR) was observed in the group taking choline, which was not consistent, whereas a marginal increase in BHR in the control and DSCG groups was observed. It is concluded that choline, an anti-inflammatory agent which acts by lowering lipophosphatidyl choline (LPC), plays an active role in subjective as well as functional improvement in bronchial asthma. However, a dose related response is yet to be established.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Albuterol / therapeutic use
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Bronchodilator Agents / therapeutic use
  • Child
  • Choline / therapeutic use*
  • Cromolyn Sodium / therapeutic use*
  • Female
  • Humans
  • Lipotropic Agents / therapeutic use*
  • Male
  • Middle Aged
  • Respiratory Function Tests
  • Treatment Outcome

Substances

  • Anti-Asthmatic Agents
  • Bronchodilator Agents
  • Lipotropic Agents
  • Choline
  • Cromolyn Sodium
  • Albuterol